Cargando…

Drugs with anti-inflammatory effects to improve outcome of traumatic brain injury: a meta-analysis

Outcome after traumatic brain injury (TBI) varies largely and degree of immune activation is an important determinant factor. This meta-analysis evaluates the efficacy of drugs with anti-inflammatory properties in improving neurological and functional outcome. The systematic search following PRISMA...

Descripción completa

Detalles Bibliográficos
Autores principales: Begemann, Marieke, Leon, Mikela, van der Horn, Harm Jan, van der Naalt, Joukje, Sommer, Iris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7528105/
https://www.ncbi.nlm.nih.gov/pubmed/32999392
http://dx.doi.org/10.1038/s41598-020-73227-5
_version_ 1783589192045953024
author Begemann, Marieke
Leon, Mikela
van der Horn, Harm Jan
van der Naalt, Joukje
Sommer, Iris
author_facet Begemann, Marieke
Leon, Mikela
van der Horn, Harm Jan
van der Naalt, Joukje
Sommer, Iris
author_sort Begemann, Marieke
collection PubMed
description Outcome after traumatic brain injury (TBI) varies largely and degree of immune activation is an important determinant factor. This meta-analysis evaluates the efficacy of drugs with anti-inflammatory properties in improving neurological and functional outcome. The systematic search following PRISMA guidelines resulted in 15 randomized placebo-controlled trials (3734 patients), evaluating progesterone, erythropoietin and cyclosporine. The meta-analysis (15 studies) showed that TBI patients receiving a drug with anti-inflammatory effects had a higher chance of a favorable outcome compared to those receiving placebo (RR = 1.15; 95% CI 1.01–1.32, p = 0.041). However, publication bias was indicated together with heterogeneity (I(2) = 76.59%). Stratified analysis showed that positive effects were mainly observed in patients receiving this treatment within 8 h after injury. Subanalyses by drug type showed efficacy for progesterone (8 studies, RR 1.22; 95% CI 1.01–1.47, p = 0.040), again heterogeneity was high (I(2) = 62.92%) and publication bias could not be ruled out. The positive effect of progesterone covaried with younger age and was mainly observed when administered intramuscularly and not intravenously. Erythropoietin (4 studies, RR 1.20; p = 0.110; I(2) = 76.59%) and cyclosporine (3 studies, RR 0.75; p = 0.189, I(2) = 0%) did not show favorable significant effects. While negative findings for erythropoietin may reflect insufficient power, cyclosporine did not show better outcome at all. Current results do not allow firm conclusions on the efficacy of drugs with anti-inflammatory properties in TBI patients. Included trials showed heterogeneity in methodological and sample parameters. At present, only progesterone showed positive results and early administration via intramuscular administration may be most effective, especially in young people. The anti-inflammatory component of progesterone is relatively weak and other mechanisms than mitigating overall immune response may be more important.
format Online
Article
Text
id pubmed-7528105
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-75281052020-10-02 Drugs with anti-inflammatory effects to improve outcome of traumatic brain injury: a meta-analysis Begemann, Marieke Leon, Mikela van der Horn, Harm Jan van der Naalt, Joukje Sommer, Iris Sci Rep Article Outcome after traumatic brain injury (TBI) varies largely and degree of immune activation is an important determinant factor. This meta-analysis evaluates the efficacy of drugs with anti-inflammatory properties in improving neurological and functional outcome. The systematic search following PRISMA guidelines resulted in 15 randomized placebo-controlled trials (3734 patients), evaluating progesterone, erythropoietin and cyclosporine. The meta-analysis (15 studies) showed that TBI patients receiving a drug with anti-inflammatory effects had a higher chance of a favorable outcome compared to those receiving placebo (RR = 1.15; 95% CI 1.01–1.32, p = 0.041). However, publication bias was indicated together with heterogeneity (I(2) = 76.59%). Stratified analysis showed that positive effects were mainly observed in patients receiving this treatment within 8 h after injury. Subanalyses by drug type showed efficacy for progesterone (8 studies, RR 1.22; 95% CI 1.01–1.47, p = 0.040), again heterogeneity was high (I(2) = 62.92%) and publication bias could not be ruled out. The positive effect of progesterone covaried with younger age and was mainly observed when administered intramuscularly and not intravenously. Erythropoietin (4 studies, RR 1.20; p = 0.110; I(2) = 76.59%) and cyclosporine (3 studies, RR 0.75; p = 0.189, I(2) = 0%) did not show favorable significant effects. While negative findings for erythropoietin may reflect insufficient power, cyclosporine did not show better outcome at all. Current results do not allow firm conclusions on the efficacy of drugs with anti-inflammatory properties in TBI patients. Included trials showed heterogeneity in methodological and sample parameters. At present, only progesterone showed positive results and early administration via intramuscular administration may be most effective, especially in young people. The anti-inflammatory component of progesterone is relatively weak and other mechanisms than mitigating overall immune response may be more important. Nature Publishing Group UK 2020-09-30 /pmc/articles/PMC7528105/ /pubmed/32999392 http://dx.doi.org/10.1038/s41598-020-73227-5 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Begemann, Marieke
Leon, Mikela
van der Horn, Harm Jan
van der Naalt, Joukje
Sommer, Iris
Drugs with anti-inflammatory effects to improve outcome of traumatic brain injury: a meta-analysis
title Drugs with anti-inflammatory effects to improve outcome of traumatic brain injury: a meta-analysis
title_full Drugs with anti-inflammatory effects to improve outcome of traumatic brain injury: a meta-analysis
title_fullStr Drugs with anti-inflammatory effects to improve outcome of traumatic brain injury: a meta-analysis
title_full_unstemmed Drugs with anti-inflammatory effects to improve outcome of traumatic brain injury: a meta-analysis
title_short Drugs with anti-inflammatory effects to improve outcome of traumatic brain injury: a meta-analysis
title_sort drugs with anti-inflammatory effects to improve outcome of traumatic brain injury: a meta-analysis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7528105/
https://www.ncbi.nlm.nih.gov/pubmed/32999392
http://dx.doi.org/10.1038/s41598-020-73227-5
work_keys_str_mv AT begemannmarieke drugswithantiinflammatoryeffectstoimproveoutcomeoftraumaticbraininjuryametaanalysis
AT leonmikela drugswithantiinflammatoryeffectstoimproveoutcomeoftraumaticbraininjuryametaanalysis
AT vanderhornharmjan drugswithantiinflammatoryeffectstoimproveoutcomeoftraumaticbraininjuryametaanalysis
AT vandernaaltjoukje drugswithantiinflammatoryeffectstoimproveoutcomeoftraumaticbraininjuryametaanalysis
AT sommeriris drugswithantiinflammatoryeffectstoimproveoutcomeoftraumaticbraininjuryametaanalysis